With cancer a leading cause of death in Japan, the market for pharmaceuticals to treat tumors is expected to grow by 5% by 2023, and to represent one fifth of the market for pharmaceuticals by 2026.
The prediction is part of a Japan Oncology Market Snapshot published by Pharma Boardroom. It predicts the largest market increase over the next two years among pharmaceuticals used to treat hepatocellular carcinoma (11%), followed by oncology drugs for the treatment of gynecologic cancers (10.5%) and leukemia (9.2%).